HP DNA - Javenech

download report

Transcript HP DNA - Javenech

HP DNA
Highly Polymerized Deoxyribonucleic Acid
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Definition
Marine Biopolymer characterized by
Its source
Its special method of extraction
Its determined physico-chimical properties
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Origin
Natural hydrosoluble substance extracted from the milt of
wild salmon
By non-denaturating technology
• protecting the superstructure of polymer
• preserving its physiological activity
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Aspect
White-cream fibers measuring several centimeters
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Solubility
Relatively soluble in water
Making a gel with low concentration (1.0 to 3.0 %)
insoluble in
• alcohol
• ethanol
• the other oganic solvents
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Metabolism
• half-life of 72 hours at rat
• elimination after 96 hours:fecal (62,8 %) and urinary (19,4 %)
• hepatic degradation in mononucleotides
• biliary elimination
• the intestine seems to retain polymerized parts of DNA and to
be rapidly saturated in part of low molecular weight
• the lymphatic tissue seems to accumulate polymerized parts
of DNA then to release them rapidly in venous blood
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Pharmacovigilance
Followed by laboratory Sterlin-Winthrop from 1985 and 1990
• administration almost without secondary effects
• excellent clinical tolerance (superior to 90 %)
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Antioxidant Properties (1)
• It retards and diminishes the formation of dienes conjuges
(joined paired),notably by its antiradical activity vis-à-vis the
hydroxyl radical (OH°–)
HPDR inhibition of free radical formation
90
78
80
72
70
58
60
% of inhibition of
DMPO-OH signal
85
65
50
40
30
HPDR
25
20
10
0
0,4
0,8
1,2
1,6
2
HPDR concentration (mg/ml)
2,4
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Antioxidant Properties (2)
•The capturing of this highly reactive radical by HP DNA
accompanies the formation of a stable product, the 8-hydroxyguanosine (8-OHDG), and avoids the formation of a new free
radical and thus terminates the process of peroxydation.
=> HP DNA protects the cells against extra cellular oxidative
aggressions.
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Antioxidant Properties (3)
• protector effect against lipoperoxydation
Ara chidonic Acid oxida tion with and without HPDR
Mesu remen t o f
con ju gated dienes OD
234 n m
6
5
Arac hidonic Ac id 2,5.10- 3 M
4
Arac hidonic Ac id / HP DR 90
µg/ml
3
2
1
0
0
2
4
6
Day s
8
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Antioxidant Properties (4)
Inhibition of lipid peroxydation by the association of vit E + HPDR in rat
hepatocytes overloaded by iron
-6
250.10 M
1mg/ml
2 mg/ml
4 mg/ml
1 mg/ml
2 mg/ml
100
90
80
70
Inhibition (%) of production
of free malonic dialdehyde
60
50
40
30
20
10
0
Vit E (250.10-6 M)
HPDR (mg/ml)
Vit E (250.10-6 M
+ HPDR (mg/ml)
4 mg/ml
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect(1)
Open clinical study : HP DNA 8OO mg/j during 30 days
• 44 asthenic adults (having no less than 15 of the 60 asthenia
symptoms present)
compared to 32 normal adults (having less than 15 of the 60
asthenia symptoms present)
•  62.7 % of the physical asthenic symptoms
•  40 % of the mental asthenic symptoms
• The scores observed in the treated asthenic patients directly
approached those patients seen as normal
•  58 of 60 of asthenia symptoms
•  many of the most debilitating symptoms
• action on asthenia by HP DNA globally is positive in 52.4% of
the cases
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (2)
Open multi-centered study: HP DNA 800 mg/day during 15days
• 688 adults (445 women and 243 men)
•spontaneous asthenia showed during the interrogation/isolated
or associated with a non evolutionary benign organic pathology
Treatment by HP DNA:
•  Behaviour Rating Scale (61 criteria)
- 64.5 % for physical asthenia, - 57.0 % for mental asthenia
• improvements more intensively marked when more severe
symptoms
• global efficacy of the treatment evaluated by researchers in
79.1% of the cases
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (3)
Amélioration de l’asthénie physique
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (4)
Improvement of psychic asthenia
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (5)
Open study
• HP DNA 400 mg/day +ascorbic acid 1 g/day during 15 days
• 6876 patients
Patients did not receive another anti-asthenia treatment (70 %
of cases)
•  fatigue at night (a reduction of more than 50% of the intense
symptoms) in 82.5 % of cases
•  fatigue in the morning in 82.9 % of cases
•  difficulty concentrating in 76.9 % of cases
•  trouble sleeping in 75 % of cases
•  trouble with appetite in 80 % of cases
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (6)
Effect of HPDR - Surve y on physical fatigue (1000 doctors)
400 mg/day of HPDR + 1 g/day of vitamin C during 15 days
% studied peo ple
90
82,9
82,5
80
76,9
80
75
70
60
Improvment > 50 %
Recovery
50
40
33,9
30
25,7
24,3
20,5
20
20
10
0
Eve ning
Tire dnes s upon
tir ednes s
wa king up
Difficulty
conc entra ting
Slee p dis orders
Appetite
dis orders
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (7)
Open clinical trial : ADN-HP 800 mg/day during 1 month
• 24 persons of more than 50 years with asthenia of which 16
had anorexia and 8 were chronic alcoholics
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Anti-asthenia effect (8)
Treatment by HP DNA
•  patients general state in 70 % of cases and  mental state in 63% of
cases
Effect of HPDR on the elderly people
(> 50 years) with 800 mg/day of HPDR after 1 month
70
Improvment (in %)
70
68
66
63
64
62
60
58
General
Improvment
Improvment in
psychological
behaviour
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on basic arthralgies (1)
Multicentric clinical study, in a double blind
• 116 patients suffering from chronic spinal problems (for a
period of more than 1 month)
• HP DNA 800 mg/day during 30 days versus placebo
Treatement by HP DNA
•  43.6 % intensity of the pain, quantified on the numeric
scale of Huskinson (versus 25.4 % with placebo)
•  32.6 % degree of functional discomfort (handicap)
(versus 25.4 % with placebo)
•  43. 3 % importance of the limitation of passive mobilization
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on basic arthralgies (2)
Effect of the HPDR on back pain (116 people - average age
= 42 years) after 30 days (daily dose of HPDR = 1g/day)
45
40
35
30
25
(%)
20
15
10
5
0
43,3
43,6
39,6
32,7
25,4
25,5
26,9
25,5
HPDR
Placebo
Reduction in painReduction in the Increase in
Overall
degree of
vertebral column improvment in
functional
mobility
general condition
difficulty
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Chondrostimulating activity (1)
Open study
• 2960 persons affected by arthrosis, with an average age of
61.1 years old
• ADN-HP 400 mg/day + complex of vitamins (B + E)
• during 1 or 2 months
Treatment by HP DNA
• at the end of the first month of treatment:
 pains in 89.5 % of cases
– 21 % were completely relieved
– 68.5 % were partially relieved
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Chondrostimulating activity (2)
Effect of HPDR on osteoarthritis
(2960 people - average age = 61 years)
with 400 mg/j of HPDR + vit B + vit E after 30 days
% people studied
83,6
90
80
68,5
70
60
50
40
30
21
20
10
0
Completely relieved
pain
Partially relieved pain
Improved physical
performance
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Chondrostimulating activity (3)
In double blind study
• 67 persons affected by arthrosis with average disability of the
knees and hips
• HP DNA 400 mg/day + complex of vitamins (B + E)
• versus diclofénac (anti-inflamatory, non-steroid)
• during 42 days
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Chondrostimulating activity (4)
Treatment by HP DNA
•  39 % pain (versus 35 % with diclofénac)
Effect of HPDR on knee or hip osteoarthritis (67 people)
of 400 mg/day of HPDR + vit E + vit B after 42 days
% of reduction in
pain
39
40
35
35
27
30
25
HPDR
20
15
13
Diclofénac
10
5
0
J21 (T0 + 21 days)
J42 (T0 + 42 days)
HP DNA
Highly Polymerized Deoxyribonucleic Acid
Chondrostimulating activity (5)
Treatment by HP DNA
•  16.1 % degree of impotence (versus 26,1 % with diclofénac)
Effect of HPDR on knee or hip osteoathritis (67 people)
with 400 mg/day of HPDR + vit B + vit E after 42 days
% of reduction of
infirmity degree
30
26,1
25
20
15,2
16,1
HPDR
15
Diclofénac
10
5
1
0
J21 (T0 + 21 days)
J42 (T0 + 42 days)
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Consolidation of dental joints (1)
Study : with a traditional local method
• 108 patients affected by periodontal pathology,
• HP DNA 1600 mg/day during 3 months
With administration of HP DNA
•  the index of dental mobility to a high of 45.7%
•  …………………………
to a low of 22.5%
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Consolidation of dental joints (2)
Success treatment for :
• 56 % of patients treated by HP DNA and local treatment
• 7 % only of patients treated with a traditional local method
Effect of HPDR for the treatment o f periodo ntics (g um) with
16 00 mg/day of HPDR after 3 months
Review of 10 8 ra ndom observations
% s tudied people
70
70
56
60
50
39
40
Loca l trea tme nt
HP DR
30
23
20
10
7
3
0
Trea tment
suc cess
Trea tment
fa ilure
Don't know
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on physical performance (1)
Study on mice
• HP DNA 200mg/day + ascorbic acid 500 mg/day during 5 days
=> amelioration of a swimming test
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on physical performance (2)
Study on dog
• HP DNA 400 mg/day ± ascorbic acid 1 g/day
• before standard exertion
•  50 % the frequency of heart exertion with HP DNA+ vit. C
•  the recuperation time after exertion:
– 50 % with HP DNA alone
– 83 % with HP DNA + vitamin C
•  elevation of cortisolemie 50 minutes after exertion:
– 71% with HP DNA alone
– 100 % with HP DNA + vitamin C
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on physical performance (3)
Study on men
• 30 athletes with an average age of 20 years old
• HP DNA 800 mg/day + vitamin C 2000 mg/day during 21 days
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on physical performance (4)
Effect of the association (1)
•  recuperation index, calculated by the Ruffier-Dickson Test
Effect on recuperation after exercise with 800 mg/day of HPDR + 2000
mg/day of vitamin C during 21 days
80
80
70
60
50
40
20
30
20
10
0
Improvment
Discordant results
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Effect on physical performance (5)
Effect of the association (2)
•  maximum oxygen intake (VO2 max)
evaluated using the Cooper test
Effect on stamina during exercise
HPDR 80 0 mg/da y + vita min C 2000 mg /day during 21 days
39,6
39,4
39,2
39
38,8
38,6
O2 consommatio n during
effort (ml/mn/kg)
38,4
38,2
38
37,8
37,6
Average at T0
Average at T0 + 21
days of treatme nt
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Regenerative action on intellectual
development in regard to psychomotor and
biometrics of subjects with mental defects
Double blind study:
HP DNA 200 - 600 mg/day versus placebo during 3 months
256 children between the ages of 6 and 21 years with average
to profound mental defects
The children have benefited by gaining mental age in cases of:
• Exogenous defects with an IQ* > 40
• A real age understanding of between 8 and 14 years
* intellectual quotient
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Immunostimulating activity (1)
In mice without spleens 4 weeks before, when injected intraperatonial 0.03 to 0.3 g/kg with HP DNA for 10 days
•  resistance vis-à-vis a parasitic infection
( time augmented for surveying the animal traits with regard to
the evidence)
•  capacity of the lymphocytes to divide and produce
interleukine 2
In vitro, HP DNA exerted a mitogene effect on the splenocytes
of naturally immune-depressed mice.
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Immunostimulating activity (2)
Study with patients:
• 66 subjects with leucopenia (leucocytes < 3000)
• a treatment with HP DNA (800-1200 mg/day for 3 weeks)
was effective in 77% of the cases, and the majority just after
the first week of treatment
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Regenerative action vis-à-vis the cicatriciels process
In mice, after the realization of experimental wounds, the
administration of HP DNA accelerated the cicatrisation:
• by  proliferative activity
• by  the number of polypoid epidermal cells
In rats, one hour after the administration of 325 mg/kg of
aspirin, the taking of HP DNA (10 to 50 mg/kg per os)
• prevented the apparition of gastric ulcers from aspirin
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Powerful radioprotective activity
Survival level after irradiation proportional to polymerization
degree of injected heterologous DNA
At rats
• 24 hours after a lethal irradiation of 1000 rœntgens
after injection of 300 g of HP DNA => definitive survival
At animal, the administration of HP DNA
•  bone marrow aplasia (anemia and leucopenia) experimental
radio-induced
•  decrease of spermatogenesis secondary to irradiation
HP DNA
•Highly Polymerized Deoxyribonucleic Acid
Potential Applications
=> To stimulate immunity
=> To accelerate the cicatrization
=> To restore the general state
=> For physical and psychic asthenia
=> To improve cognitive performances
•  intellectual quotient
•  memorization
=> To improve physical performance
•  VO2 max
•  recuperation time
=> To treat basic arthralgies and arthrosis
=> To reduce the secondary effects of radiotherapy
HP DNA
Highly Polymerized Deoxyribonucleic Acid
HP DNA, a marine DNA highly polymerized with
a strong antioxidant power, with potential
applications in health…
For asthenia, arthrosis, immunodeficiency,
troubles of cicatrisation,…